Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tolerance Does Not Develop Toward Liraglutide's Glucose-Lowering Effect.

Tuuli Sedman1,2, Eero Vasar1,2, Vallo Volke1,2,3

  • 1Department of Physiology, Institute of Biomedicine and Translational Medicine, University of Tartu, 50411 Tartu, Estonia.

The Journal of Clinical Endocrinology and Metabolism
|April 6, 2017
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Milk extracellular vesicles reveal insulin resistance status in peripartum dairy cows.

The veterinary quarterly·2026
Same author

Sex-specific changes in the hippocampal proteome of Negr1<sup>-/-</sup> mice: insight into the mechanisms of neuropsychiatric disorders.

Biology of sex differences·2026
Same author

Fecal microbiome predicts treatment response after the initiation of semaglutide or empagliflozin uptake.

Scientific reports·2026
Same author

Negr1 deficiency alters glutamate signalling and kynurenine pathway in a mouse model of psychiatric disorders.

Scientific reports·2026
Same author

Negr1 Deficiency Modulates Sex-Specific Neurobehavioral Adaptations to Social Isolation.

Brain sciences·2025
Same author

Comparison of Validity and Reliability of Manual Consensus Grading vs. Automated AI Grading for Diabetic Retinopathy Screening in Oslo, Norway: A Cross-Sectional Pilot Study.

Journal of clinical medicine·2025

Tolerance does not appear to develop to the glucose-lowering effects of glucagon-like peptide-1 receptor agonists with prolonged use. This study found chronic liraglutide treatment remained effective in healthy subjects.

Area of Science:

  • Endocrinology
  • Pharmacology

Background:

  • Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are effective antidiabetic drugs with low hypoglycemia risk.
  • Tolerance to some GLP-1 RA effects, like gastric motility, is known, but tolerance to glucose-lowering effects is unstudied.

Purpose of the Study:

  • To investigate if tolerance develops to the glucose-lowering effects of GLP-1 RAs during chronic use.
  • To test the hypothesis of tolerance development with liraglutide in healthy individuals.

Main Methods:

  • A 21-day open-label trial with 10 healthy volunteers using 0.6 mg daily liraglutide.
  • Assessed glucose-lowering and insulin secretion via graded glucose infusion tests before and after chronic treatment.

Main Results:

Related Experiment Videos

  • Liraglutide significantly lowered glucose levels and enhanced insulin secretion.
  • Chronic liraglutide administration showed comparable efficacy to acute treatment.
  • No significant change in the dose-response relationship for insulin secretion was observed.

    • Conclusions:

    • Results largely refute the hypothesis of tolerance development to liraglutide's glucose-lowering effects with prolonged use in healthy humans.
    • Sustained efficacy of liraglutide suggests it remains a potent option for glucose control without diminishing effectiveness over time.